Lung Cancer Treatments and Mutations

SEP 8, 2026 · JOURNAL ARTICLE

Risk-adaptive management of stage III NSCLC in the perioperative immunotherapy era: a critical synthesis and clinical framework

Frontiers in Oncology

A critical synthesis and clinical framework addressing heterogeneous stage III NSCLC management in the perioperative immunotherapy era, integrating recent phase III trial evidence with expert consensus on risk-adapted strategies.

SEP 8, 2026 · REVIEW

Economic evaluations of next-generation sequencing for targeted therapy in non-small cell lung cancer: a systematic review

Frontiers in Public Health

Systematic review of economic evidence synthesizing 18 model-based evaluations to inform policy on NGS adoption in NSCLC, with contextual conclusions about cost-effectiveness variability rather than a single definitive clinical or economic finding.

SEP 8, 2026 · JOURNAL ARTICLE

Mutant TP53 physically sequesters FOXP3 to abrogate PD-L1 transcriptional regulation and drive immune evasion in lung adenocarcinoma: multi-scale computational evidence supporting a candidate interaction

BMC Bioinformatics

Multi-scale computational prediction of a candidate mutp53-FOXP3 interaction mechanism, supported by associational survival data and in silico modelling but lacking experimental validation of physical sequestration or functional causality.

SEP 7, 2026 · JOURNAL ARTICLE

Precision Oncology in Non-Small Cell Lung Cancer: Integrating Molecular Diagnostics, Targeted Therapies, and Resistance Mechanisms

Genes

A structured narrative review synthesizing evidence from 99 foundational studies and clinical documents to provide organized guidance on molecular biomarkers, diagnostic methods, and resistance mechanisms in NSCLC precision oncology, rather than reporting original trial data.

SEP 7, 2026 · JOURNAL ARTICLE

Toward Fit‐for‐Purpose Data for Drug Assessment in Non‐small Cell Lung Cancer: A Core Dataset

Clinical Pharmacology & Therapeutics

This is a consensus-derived core dataset specification developed through systematic literature review and multi-stakeholder expert meetings to standardize real-world data collection for NSCLC drug evaluation.

SEP 7, 2026 · JOURNAL ARTICLE

Structural classification of EGFR mutations and its association with TKI efficacy against compound and co-mutations in a Chinese NSCLC cohort: a single-center retrospective analysis

BMC Cancer

A single-center retrospective cohort study with clear findings on EGFR mutation subtypes and TKI sensitivity in a defined population, but limited by retrospective design, lack of survival or clinical outcome detail, and modest sample sizes for the key comparison groups.

SEP 7, 2026 · JOURNAL ARTICLE

Efficacy and Safety of Savolitinib Plus Osimertinib in EGFR-Mutant, MET-Aberrant Advanced Non–Small Cell Lung Cancer

American Journal of Clinical Oncology

Meta-analysis of single-arm cohorts showing encouraging efficacy (ORR 53.9%) and manageable safety, but limited by lack of randomized comparator and reliance on surrogate endpoints; requires confirmatory RCT evidence.

SEP 7, 2026 · JOURNAL ARTICLE

An exploratory case series of sequential stereotactic body radiotherapy and tislelizumab after platinum-doublet chemotherapy in stage IIIB/C–IV non-squamous NSCLC

Frontiers in Immunology

Single-center exploratory pilot case series with deliberate selection bias, small sample, and descriptive endpoints only; generates hypothesis-building observations insufficient for definitive therapeutic conclusions.